Antibody-Drug Conjugates Stability White Paper

Antibody-drug conjugate stability remains a critical factor in ensuring their safety, efficacy, and overall performance. The inherent complexity of ADCs introduces multiple stability challenges, making it essential to understand the factors that can impact their structural integrity and functional activity throughout their lifecycle.

In Part II of our Current Trends in Antibody-Drug Conjugates Characterization series, focused on ADC analytical development, our expert Ashleigh Wake explores the key factors influencing ADC stability. This includes formulation considerations, strategies for designing stability studies—such as forced degradation—and the analytical approaches used to assess and monitor stability.

This paper provides valuable insights to support the development of robust, stable ADC products and to help navigate the analytical challenges associated with these advanced therapeutics. 

Want to ensure the stability and performance of your ADC therapeutics?

Download the full white paper to explore expert insights on stability challenges, formulation strategies, and advanced analytical approaches for antibody-drug conjugates.